A cross-sectional study provided information on the prevalence of lichen planopilaris (LPP), a type of scarring alopecia, among US adults seeing a dermatologist and the most common treatments ... The Globe and Mail: Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Please provide your email address to receive an email when new articles are posted on . Brepocitinib downregulated key inflammatory biomarkers in cicatricial alopecias.

Understanding the Context

Brepocitinib also improved ... Yahoo Finance: Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye ... Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA ... Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye ...

Key Insights

Lichen planopilaris (LPP) is a chronic inflammatory scalp disorder that represents a follicular variant of lichen planus. It is characterized by perifollicular erythema, hyperkeratosis, and ...